Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of Its Potential ...

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential ...

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, Huge Biopharma…

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the...

Breakthrough MS Drug Shows Promise in Mobility Recovery, Heads to Phase 2 Trial with New Oral Format

New oral formulation of MS drug advances to human trials after successful animal mobility tests. Leading CDMO partnership accelerates Phase 2 development. See trial details.